Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

simeprevir

Known as: HSDB 8227, N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide, Simeprevir [Chemical/Ingredient] 
An orally bioavailable inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat population and are at risk of… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND & AIMS The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)‐infected… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Simeprevir (TMC435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS In a Japanese Phase II study, the hepatitis C virus NS3/4A protease inhibitor simeprevir demonstrated potent… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
UNLABELLED The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?